Pfizer has agreed to acquire obesity drug developer Metsera for up to $86.25 a share, surpassing Novo Nordisk's final offer. This move marks Pfizer's latest effort to compete in the lucrative weight-loss drug market. The deal follows a bidding war and legal disputes initiated by Pfizer against Metsera and Novo Nordisk.